5:49 PM
 | 
Jan 31, 2013
 |  BC Extra  |  Clinical News

Vanda slides on tasimelteon discontinuation for MDD

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) slid $0.32 to $4.02 on Thursday after the company said it discontinued development of tasimelteon to treat major...

Read the full 93 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >